Anti-Coagulants - Saudi Arabia

Saudi Arabia

The Anti-Coagulants market in Saudi Arabia is anticipated to witness a substantial increase in revenue, projected to reach US$167.60m in 2024.
This growth is expected to continue, with an annual growth rate (CAGR 2024-2029) of 7.08%.
As a result, the market volume is estimated to reach US$235.90m by 2029.
When compared to other countries worldwide, United States is expected to generate the highest revenue in the Anti-Coagulants market, with US$16,740.00m in 2024.
In Saudi Arabia, there is an increasing demand for novel oral anti-coagulants due to their convenience and efficacy.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Saudi Arabia has been experiencing significant growth in recent years.

Customer preferences: One of the primary reasons for the growth of the Anti-Coagulants market in Saudi Arabia is the rise in the number of patients suffering from cardiovascular diseases. According to recent statistics, cardiovascular diseases are the leading cause of death in Saudi Arabia. As a result, there has been an increasing demand for Anti-Coagulants in the country.

Trends in the market: The Anti-Coagulants market in Saudi Arabia has been witnessing a shift towards novel oral anticoagulants (NOACs) in recent years. NOACs are more effective than traditional anticoagulants and have fewer side effects. This has led to an increase in the adoption of NOACs among patients in the country.

Local special circumstances: Another factor contributing to the growth of the Anti-Coagulants market in Saudi Arabia is the government's focus on improving healthcare infrastructure in the country. The government has been investing heavily in the healthcare sector, which has led to an increase in the availability of healthcare facilities and services.

Underlying macroeconomic factors: The growth of the Anti-Coagulants market in Saudi Arabia can also be attributed to the country's growing economy. The country has been experiencing steady economic growth in recent years, which has led to an increase in the purchasing power of consumers. This, in turn, has led to an increase in the demand for healthcare services, including Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.